Calendar

To view more alumni events, click here.

Mar
1
Tue
ICM Distinguished Seminar Series presents “Systems Pharmacology: From Testing Virtual Patients to Treating Real Ones”
Mar 1 @ 11:00 am – 12:00 pm

The Institute for Computational Medicine Distinguished Seminar Series 2015-2016 presents Saroja Ramanujan, Principal Scientist  and Group Lead, Translational and Systems Pharmacology for PKPD Sciences, Genentech. Inc. at 11 a.m. on Tuesday, March 1 in Clark Hall 110.

saroja ramanujan photoThe title of her lecture is “Systems Pharmacology: From Testing Virtual Patients to Treating Real Ones.”

If you cannot make it to campus, the seminar will be video-conferenced to Traylor 709 on the Johns Hopkins Medicine campus. Lunch will be provided at noon at the Homewood site.  If you are interested in meeting with Dr. Ramanujan during her visit, please participate in this doodle poll. Spaces are limited.

Information on ICM seminars and links to previous talks can be found here.

Apr
5
Tue
ICM’s Distinguished Seminar Series presents Sridevi Sarma
Apr 5 @ 11:00 am – 12:00 pm

Sarma-Sridevi72-300x190The Institute for Computation Medicine’s Distinguished Seminar Series will present Sridevi Sarma of the Department of Biomedical Engineering at 11 a.m. on Tuesday, April 5 in Clark Hall 110 on the Johns Hopkins Homewood campus. The seminar will also be video-teleconferenced to Traylor 709 on the Hopkins Medical Campus.

The title of Sarma’s seminar is “Network Dynamics of the Brain and Influence of the Epileptic Seizure Onset Zone.”

Lunch will be provided to Homewood attendees only.

Information about ICM seminars and links to previous talks can be found here.

Apr
4
Tue
ICM Distinguished Seminar Series presents “Steering Cancer Evolution: Harnessing Phenotypic Heterogeneity to Design Better Therapies”
Apr 4 @ 11:00 am – 12:00 pm
ICM Distinguished Seminar Series presents "Steering Cancer Evolution: Harnessing Phenotypic Heterogeneity to Design Better Therapies" @ 110 Clark Hall, Johns Hopkins Homewood campus

Alexander, R.A. Anderson, the co-director of Integrated Mathematical Oncology and senior member of the Moffitt Cancer Center, will present on April 4, 2017, as part of the Institute for Computational Medicine’s Distinguished Seminar Series. The title of his presentation is “Steering Cancer Evolution: Harnessing Phenotypic Heterogeneity to Design Better Therapies.”

The seminar begins at 11 a.m. in Clark Hall 110 on the Homewood campus, and it will be video-teleconferenced to Traylor 709 on the Johns Hopkins School of Medicine campus. Click here to view webcast. Lunch will provided to those in attendance on the Homewood campus.

 

Abstract: Heterogeneity in cancer is an observed fact, both genetically and phenotypically. Cell-to-cell variation is seen in all aspects of cancer, from early development to invasion and subsequent metastasis. This heterogeneity is also at the heart of why many cancer treatments fail, as it facilitates the emergence of drug resistance. The complex spatial and temporal process by which tumors initiate, grow and evolve is a major focus of the oncology community and one that requires the integration of multiple disciplines. Tumor heterogeneity at the tissue scale is largely due to ecological variations in 
terms of the tumor habitat driven by spatially heterogeneous vascularity, which is
readily observed on cross sectional imaging. Molecular techniques have 
historically averaged genomic signals from large numbers of cells obtained in a 
single biopsy site, thus smoothing and potentially hiding underlying spatial 
variations. The complex dialogue between tumor cells and
 environment that produces intra- and inter-tumoral heterogeneity is
fundamentally governed by Darwinian dynamics. That is, local micro-
environmental conditions select phenotypic clones that are best adapted to
 survive and proliferate and, conversely, the phenotypic properties of the cells affect the 
environmental properties. While these complex interactions have enormous 
clinical implications because they promote resistance to therapy, the dynamics 
are impossible to fully capture via experimentation alone.

Here we present an integrated theoretical/experimental approach to develop dynamical models of the complex multiscale interactions that manifest as temporal and spatial heterogeneity in cancers and ultimately govern tumor response and resistance to therapy. Specifically, we examine the impact of micro-environmental modulation on cancer evolution both in silico, using a hybrid multiscale mathematical model, and in vivo, using three different spontaneous murine cancers. These models allow the tumor to be steered into a less invasive pathway through the application of small but selective biological force. Our long term goal is explicitly translational as we focus our integrated approach on an emerging cancer treatment paradigm that actively harnesses evolutionary dynamics to improve patient outcomes.

Apr
6
Thu
ICM Distinguished Seminar Series presents “Using Modeling to Inform Critical Decisions: Three Stories of Preclinical Molecules”
Apr 6 @ 3:30 pm – 4:30 pm
ICM Distinguished Seminar Series presents "Using Modeling to Inform Critical Decisions: Three Stories of Preclinical Molecules" @ 107 Latrobe Hall

Yasmin Hashambhoy-Ramsay will present “Using Modeling to Inform Critical Decisions: Three Stories of Preclinical Molecules” on April 6 in a presentation hosted by the Institute for Computational Medicine.

Bio: Yasmin Hashambhoy-Ramsay is a computational biologist working in the biotech industry in Cambridge, Massachusetts. She was born and raised in Toronto and obtained her undergraduate degree in Applied Mathematics and Engineering at Queen’s University. A strong desire to help patients drew her to Johns Hopkins, and she is a proud alumna of the BME PhD program. She graduated from Rai Winslow’s lab and worked as a postdoctoral fellow with Feilim Mac Gabhann. As a Principal Scientist at Merrimack Pharmaceuticals, she used modeling to help advance drug development on various antibody and nanotherapeutic preclinical teams. She looks forward to starting a new position at Jounce Therapeutics in April as a Senior Bioinformatics Scientist.

Abstract: When I was a graduate student and postdoc at Johns Hopkins, I loved doing biomedical research. The thought of taking rational, engineering approaches to understand biological mechanisms really appealed to me; however, I wasn’t sure if folks in industry appreciated these approaches too. It turns out that they do, and lots of pharmaceutical companies use computational biology to inform critical decisions. Over the past five years, I have worked on a number of preclinical teams at Merrimack Pharmaceuticals. In this talk, I will share three stories describing how I used different modeling approaches to answer critical questions that helped advance the development of early stage oncology drugs.

Feb
28
Wed
2018 Computational Medicine Night
Feb 28 @ 5:00 pm – 7:00 pm

Computational Medicine Night is a networking event geared towards undergraduates who are interested in learning about the academic discipline of Computational Medicine and the research conducted in ICM labs. The event showcases undergraduate research and provides a forum for interested students to ‘Meet & Eat’ with ICM faculty, students, and postdoctoral fellows, to gather information about the Computational Medicine Minor, and to ask questions. Click here for a detailed event agenda and list of presenters and panelists.

Please register here to attend. Registration deadline: Feb. 21.

Back to top